Deregulation of epigenetic pathways is now recognized as an event that occurs frequently in cancer, and understanding the mechanistic role of these epigenetic factors may leadto the development of new treatments for patients with cancer1. The Polycomb group (PcG) proteins are examples of epigenetic regulators with established roles in cancer2.